A RELIABILITY-BASED ROUTING PROTOCOL FOR VEHICULAR AD-HOC NETWORKS

Vehicular Ad hoc NETworks (VANETs), an emerging technology, would allow vehicles to form a self-organized network without the aid of a permanent infrastructure. As a prerequisite to communication in VANETs, an efficient route between communicating nodes in the network must be established, and the routing protocol must adapt to the rapidly changing topology of vehicles in motion. This is one of the goals of VANET routing protocols. In this thesis, we present an efficient routing protocol for VANETs, called the Reliable Inter-VEhicular Routing (RIVER) protocol. RIVER utilizes an undirected graph that represents the surrounding street layout where the vertices of the graph are points at which streets curve or intersect, and the graph edges represent the street segments between those vertices. Unlike existing protocols, RIVER performs real-time, active traffic monitoring and uses this data and other data gathered through passive mechanisms to assign a reliability rating to each street edge. The protocol then uses these reliability ratings to select the most reliable route. Control messages are used to identify a node’s neighbors, determine the reliability of street edges, and to share street edge reliability information with other nodes

Imaging biomarker roadmap for cancer studies.

Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use.Development of this roadmap received support from Cancer Research UK and the Engineering and Physical Sciences Research Council (grant references A/15267, A/16463, A/16464, A/16465, A/16466 and A/18097), the EORTC Cancer Research Fund, and the Innovative Medicines Initiative Joint Undertaking (grant agreement number 115151), resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in kind contribution